Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential

Author(s): Ma Su, Weiwei Wang, Feng Liu*, Huanqiu Li*

Journal Name: Current Medicinal Chemistry

Volume 28 , Issue 3 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Inflammation is the body’s immune system’s fast coordinating response to irritants caused by pathogens, external injuries, and chemical or radiation effects. The nucleotidebinding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome is a critical component of the innate immune system. The dysfunction of NLRP3 inflammasome contributes to various pathogeneses of complex diseases, such as uncontrolled infection, autoimmune diseases, neurodegenerative diseases, and metabolic disorders. This review describes recent progress on the discovery of NLRP3 inflammasome inhibitors and their therapeutic potential.

Methods: Based on the mechanism of NLRP3 activation, several types of NLRP3 inhibitors are described and summarized according to their origins, structures, bioactivity, and mechanism of action. Structure-Activity Relationship (SAR) is also listed for different scaffolds, as well as effective pharmacophore.

Results: Over one-hundred papers were included in the review. The development of NLRP3 inhibitors has been described from the earliest glyburide in 2001 to the latest progress in 2019. Several series of inhibitors have been categorized, such as JC-series based on glyburide and BC-series based on 2APB. Many other small molecules such as NLRP3 inhibitors are also listed. SAR, application in related therapeutic models, and five different action mechanisms are described.

Conclusion: The findings of this review confirmed the importance of developing NLRP3 inflammasome inhibitors. Various NLRP3 inhibitors have been discovered as effective therapeutic treatments for multiple diseases, such as type II diabetes, experimental autoimmune encephalomyelitis, stressrelated mood disorders, etc. The development of a full range of NLRP3 inflammasome inhibitors is still at its foundational phase. We are looking forward to the identification of inhibitory agents that provide the most potent therapeutic strategies and efficiently treat NLRP3 inflammasome-related inflammatory diseases.

Keywords: NLRP3 inflammasome, inhibitors, inflammatory diseases, interleukin-1β, innate immunity, therapeutic potential.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 01 February, 2021
Page: [569 - 582]
Pages: 14
DOI: 10.2174/0929867327666200123093544
Price: $65

Article Metrics

PDF: 189